Showing 18,021 - 18,040 results of 46,478 for search '(( 5 ((wt decrease) OR (mean decrease)) ) OR ( 50 ((ng decrease) OR (a decrease)) ))', query time: 0.91s Refine Results
  1. 18021

    Table 1_Obinutuzumab in systemic lupus erythematosus: a real-world experience.docx by Chunmei Wu (3202050)

    Published 2025
    “…Mean SLEDAI-2K decreased from 11.75 ± 9.31 (range: 0 to 46) to 1.45± 1.93 (range: 0 to 8). …”
  2. 18022

    Enhancement of biological effectiveness of carbon-ion beams by applying a longitudinal magnetic field by Taku Inaniwa (6239012)

    Published 2019
    “…</p> <p><b>Methods and materials:</b> Human cancer and normal cell lines were exposed to low (12 keV/<i>μ</i>m) and high (50 keV/<i>μ</i>m) linear energy transfer (LET) carbon-ion beams under the longitudinal magnetic fields of <i>B</i><sub>//</sub> = 0, 0.1, 0.2, 0.3, or 0.6 T generated by a solenoid magnet. …”
  3. 18023

    Gingival recession treatment with concentrated growth factor membrane: a comparative clinical trial by Serap Karakış AKCAN (8650455)

    Published 2020
    “…A statistically significant decrease was observed in CAL, RD, and RW, and KTT increased in all groups at three and six months compared with the baseline. …”
  4. 18024
  5. 18025
  6. 18026
  7. 18027
  8. 18028

    Influence of Solubilizing Group Removal Rate on the Morphology and Crystallinity of a Diketopyrrolopyrrole-Based Compound by Shabi Thankaraj Salammal (1864396)

    Published 2014
    “…This means that, when the heating rate is decreased from 50 to 0.1 °C/min, the crystallinity of DPP-4T powder decreases from 49% to 34%, and the grain size of DPP-4T film reduces from 976 to 344 nm. …”
  9. 18029

    Influence of Solubilizing Group Removal Rate on the Morphology and Crystallinity of a Diketopyrrolopyrrole-Based Compound by Shabi Thankaraj Salammal (1864396)

    Published 2014
    “…This means that, when the heating rate is decreased from 50 to 0.1 °C/min, the crystallinity of DPP-4T powder decreases from 49% to 34%, and the grain size of DPP-4T film reduces from 976 to 344 nm. …”
  10. 18030

    Plots of gene expression values for <i>SOX5</i>, <i>COL2A1</i>, <i>ELN</i>, <i>B2M</i>, <i>CASP8</i>, <i>CASP9</i>, and <i>IL1A</i> normalized to large ribosomal fraction, <i>P0</i... by Narihiko Hirano (11104945)

    Published 2021
    “…Error bars represent standard error of the mean for normalized gene expression values. <i>SOX6</i> or <i>SOX9</i> = SRY (sex determining region Y)-box 6 or 9.…”
  11. 18031

    Data Sheet 1_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  12. 18032

    Data Sheet 2_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  13. 18033

    Data Sheet 3_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  14. 18034

    Data Sheet 4_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”
  15. 18035
  16. 18036

    Spread of a DENV mutant with defective 2’-O-methylation of the viral RNA genome. by Bianca Schmid (555102)

    Published 2015
    “…A549-IFIT1deGFP cells were infected with the DENV-faR E217A mutant at a MOI of 0.1 TCID<sub>50</sub>/cell. …”
  17. 18037
  18. 18038

    Electrochemistry as a Complementary Technique for Revealing the Influence of Reducing Agent Concentration on AgNPs. by Sapokazi Timakwe (14127576)

    Published 2023
    “…This process ended up in the formation of large aggregates that decrease the active surface area and therefore result in a significant decrease in their unique properties. …”
  19. 18039
  20. 18040